Core Viewpoint - InflaRx N.V. is focusing its resources on izicopan, an anti-inflammatory therapeutic, following positive Phase 2a results in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) [2][3] Financial Results - For the year ended December 31, 2025, InflaRx reported a net loss of €45.6 million, or €0.68 per ordinary share, compared to a net loss of €46.1 million, or €0.78 per ordinary share, for 2024 [20] - Total funds available as of December 31, 2025, amounted to approximately €46.2 million, which includes €16.0 million in cash and cash equivalents and €30.2 million in marketable securities [21] - Marketing and sales expenses decreased by €2.3 million to €4.5 million for the year ended December 31, 2025, primarily due to lower external service costs [15] - Research and development expenses decreased by €9.6 million to €25.7 million, mainly due to lower costs from manufacturing development activities and clinical trials [16] Business Update - InflaRx is in active discussions with the FDA regarding the design of a Phase 2b trial for izicopan in HS and expects to finalize communications soon [2][3] - The company plans to conduct a pharmacokinetic bridging study in China to expedite proof-of-concept studies for izicopan in additional indications [6] - InflaRx aims to host a virtual Capital Markets Day to provide insights into izicopan's clinical development path and market opportunities [4] Clinical Development - Izicopan has shown promising Phase 2a data, indicating rapid and meaningful reductions in abscesses and nodules in HS, with improvements in various clinical measures [7][9] - In CSU, izicopan demonstrated improvements in clinical measures that exceed historical placebo levels, particularly in patients with severe disease [10] - The company is considering further development of izicopan in CSU, with a potential market opportunity exceeding $1 billion [10] Pipeline and Strategy - InflaRx is reviewing additional development opportunities for izicopan in ANCA-associated vasculitis (AAV), highlighting its best-in-class potential due to its differentiated safety profile [5][8] - The company is actively engaging with potential collaborators to expedite its pipeline development goals [8]

Core Insights - InflaRx N.V. announced an oral presentation of its Phase 3 study data for vilobelimab in pyoderma gangrenosum at the 2026 American Academy of Dermatology Annual Meeting [1][2] Company Overview - InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics, utilizing proprietary anti-C5a and anti-C5aR technologies to develop specific inhibitors targeting the complement activation factor C5a and its receptor C5aR [3] - The company's lead program is izicopan (INF904), an orally administered small molecule inhibitor that has shown promising pharmacokinetic and pharmacodynamic characteristics in Phase 1 and Phase 2a clinical studies [3] - InflaRx has also developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has demonstrated clinical activity and tolerability in multiple studies [3] Upcoming Presentation Details - The oral presentation titled "Vilobelimab Treatment for Ulcerative Pyoderma Gangrenosum: Results from a Multicenter, Randomized, Placebo Controlled Phase 3 Trial" will be presented by Dr. Benjamin Kaffenberger on March 28, 2026, from 2:24 to 2:36 PM MT at the Bellco Theatre 3 [2]

Summary of InflaRx Conference Call Company Overview - **Company**: InflaRx (NasdaqGS: IFRX) - **Focus**: Development of izicopan, a C5AR molecule inhibitor, for various immunological conditions, including hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) [1][2] Key Points Drug Development and Pipeline - **Izicopan**: Positioned as a best-in-class potential drug targeting the complement terminal pathway, which is significant in various immunological diseases [1] - **Clinical Trials**: Completed a Phase 2a trial for izicopan in HS and CSU, with promising early efficacy signals [2][5] - **Regulatory Discussions**: Ongoing discussions with the FDA regarding the regulatory path and potential new endpoints for clinical trials [2][13] Efficacy Data - **HS Data**: The drug showed a significant reduction in lesions and draining tunnels, with 50% of patients in the high-dose group free of draining tunnels after four weeks [7][8] - **Pain Reduction**: Notable pain reduction was reported across all dosing groups, which is a critical factor for patient quality of life [5][8] - **HiSCR Endpoint Issues**: The current HiSCR endpoint has shown variability in placebo responses, complicating trial outcomes. A modified HiSCR endpoint is being discussed with the FDA [12][22] Market Opportunities - **ANCA Vasculitis**: InflaRx is exploring opportunities in ANCA vasculitis, a serious condition with significant unmet medical needs [3][34] - **Avacopan Market Dynamics**: The potential withdrawal of avacopan from the market due to safety concerns presents an opportunity for izicopan, which does not share the same liver toxicity issues [36][41] Financial Position and Strategy - **Funding**: The company is funded into mid-2027 and is exploring collaborations with pharmaceutical companies to expand the potential applications of izicopan [32][33] - **Capital Markets Day**: An upcoming event is expected to provide clarity on the development path for HS and other indications, as well as potential collaborations [30] Future Directions - **Exploratory Studies**: Initiating PK bridging studies in China to facilitate faster and more cost-effective data generation for different indications [59][60] - **Focus on CSU**: Despite mixed results in CSU, there is a belief in the drug's potential, particularly in severe cases, and plans to further explore this indication as funding allows [56] Additional Insights - **Regulatory Challenges**: The company acknowledges the complexities of trial design and the need for larger patient cohorts to achieve statistically significant results [20][22] - **Collaborative Efforts**: Engaging with other companies to explore alternative indications and enhance the drug's market potential [58] This summary encapsulates the critical aspects of InflaRx's current status, drug development efforts, market opportunities, and strategic direction as discussed in the conference call.

Summary of InflaRx Conference Call Company Overview - **Company**: InflaRx - **Focus**: Biopharmaceutical company specializing in anti-C5a and C5a inhibitors for inflammatory diseases, including hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) [1][2] Core Points and Arguments Drug Development - **Izicopan**: A new oral inhibitor targeting C5a receptor 1, showing biologic-like efficacy in HS and CSU [3] - **Mechanism**: High potency on target engagement, with potential to be transformative in anti-inflammatory diseases [3] - **Pipeline**: Focused on broader inflammatory and immunology (I&I) space, with cash funding until mid-2027 [4] Competitive Positioning - **Best-in-Class Potential**: Studies indicate izicopan has a differentiated pharmacokinetic (PK) profile compared to marketed comparator avacopan, showing a 10x increase in area under the curve and a 3x higher peak [12][13] - **Safety Profile**: Izicopan has a 36-fold less engagement with CYP3A4/5, reducing the risk of liver toxicity [14] Clinical Trials and Results - **Phase II Study**: Completed in HS and CSU, showing significant reductions in abscess and inflammatory nodules, particularly in the high-dose group [19][24] - **Draining Tunnels**: 50% of patients in the high-dose group achieved zero draining tunnels by week four, indicating a meaningful early response [27] - **Pain Reduction**: Notable improvements in skin pain, with up to 75% of patients achieving a 30% improvement on the numeric rating scale [31] Market Opportunity - **ANCA-Associated Vasculitis**: Estimated market potential of over $1 billion, with current sales around $700 million globally [41] - **Differentiated Label Potential**: Opportunity to position izicopan as corticosteroid-sparing due to its unique mechanism and safety profile [42][43] Future Directions - **Regulatory Discussions**: Active discussions with the FDA regarding the development path for izicopan, with updates expected in spring [34] - **Chronic Spontaneous Urticaria**: Initial data shows promise, but HS remains the primary focus for development [36] Additional Important Content - **Patient Impact**: Emphasis on the significant social and physical burden of HS, highlighting the need for effective treatments [20] - **Comparative Analysis**: Izicopan's early efficacy in reducing draining tunnels and pain is positioned favorably against existing treatments [32][33] - **Long-term Efficacy**: Continued improvement in symptoms observed even after cessation of treatment, indicating potential for sustained benefits [30] This summary encapsulates the key points discussed during the conference call, focusing on InflaRx's strategic direction, drug development, clinical results, and market opportunities.

Summary of InflaRx Conference Call Company Overview - **Company**: InflaRx - **Industry**: Biotechnology - **Headquarters**: Germany and the U.S. - **IPO**: Listed on NASDAQ in 2017 - **Focus**: Development of drugs targeting terminal complement inhibition, specifically C5a and C5a receptor 1 Key Molecules - **Vilobelimab**: Antibody targeting C5a - **Izicopan**: Small molecule targeting C5a receptor 1 - Recently completed a positive proof of concept Phase 2a study [2][5] Differentiation of Izicopan - **Pharmacological Properties**: - Higher bioavailability and plasma levels compared to avacopan (Amgen's drug) - Faster onset of receptor inhibition, achieving peak levels in days versus avacopan's 13 weeks [5][6] - Significantly lower inhibition of CYP3A4, reducing potential drug-drug interactions [6] - **Safety Profile**: - No observed hepatotoxicity in 200 treated patients, contrasting with avacopan's reported issues [8][9] Market Opportunities - **Potential Market Impact**: If avacopan were withdrawn, InflaRx sees an opportunity to position izicopan favorably [13] - **Hidradenitis Suppurativa (HS)**: - Conducted a 28-day study showing promising results, including reduction of draining tunnels and pain [15][16] - Data compared favorably to existing treatments, indicating a potential best-in-class profile [27] Future Development Plans - **Next Steps**: - Planning a Phase 2B study, as the initial four-week trial does not suffice for pivotal trials [23] - Ongoing discussions with the FDA regarding dosing and trial design [21][25] - **Capital Markets Day**: Expected in spring, with disclosures on HS and other indications [24][36] Financial Position - **Cost Reduction**: Fixed costs reduced by approximately 30% due to the deprioritization of vilobelimab and related activities [33] Additional Indications - **Chronic Spontaneous Urticaria (CSU)**: Encouraging data suggests potential for further trials, contingent on resources [30][32] Conclusion InflaRx is positioned to leverage its differentiated drug izicopan in the competitive landscape of autoimmune diseases, particularly HS and potentially CSU, while maintaining a strong safety profile and reducing operational costs. The upcoming Capital Markets Day will provide further insights into their strategic direction and clinical development plans.

Core Viewpoint - InflaRx N.V. is implementing cost-reduction measures to extend its cash runway and focus resources on the development of izicopan, a potential best-in-class C5aR inhibitor for hidradenitis suppurativa (HS) and other inflammatory and immunological (I&I) indications [1][2]. Financial and Operational Restructuring - The company is streamlining its organizational structure and discontinuing non-essential activities outside the development of izicopan to improve capital efficiency [3]. - InflaRx is reducing its workforce by approximately 30% and significantly cutting spending related to Gohibic (vilobelimab), which will incur a one-time charge of about $7 million, primarily a non-cash charge for inventory write-off [4]. - These actions are expected to create a leaner cost structure, allowing for substantial reductions in operating expenses and extending the cash runway to mid-2027 [4]. Development Focus on Izicopan - InflaRx is prioritizing resources for izicopan, which has shown a favorable pharmacokinetic/pharmacodynamic profile and potential to address HS, chronic spontaneous urticaria (CSU), and other I&I indications [7]. - The company is in active discussions with the FDA regarding the Phase 2b study design for izicopan in HS, aiming to differentiate it from existing therapies [8]. - A PK bridging study in China is planned for 2026 to expedite proof of concept studies for izicopan in additional geographies [12]. Clinical Progress and Future Plans - InflaRx continues to make progress toward Phase 2b readiness for izicopan in HS and plans to present Phase 2a datasets for izicopan in HS and CSU at medical conferences later this year [11][10]. - The company intends to host a virtual Capital Markets Day in spring 2026 to showcase the clinical utility and commercial potential of izicopan [13]. Product Overview - Izicopan (INF904) is an orally administered small molecule inhibitor of the C5a receptor, demonstrating anti-inflammatory effects in pre-clinical and human studies, with a favorable safety profile and significant efficacy in reducing symptoms in HS and CSU patients [14][15].